Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14956282 | 0.91 | MEN1 (0.31) | ACHEMEN1KMT2A | |
| SCHEMBL28014243 | 0.89 | — | — | |
| SCHEMBL6401841 | 0.83 | ALDH1A1 (0.32) | ALDH1A1TSHRCYP3A4SMN1; SMN2 | |
| SCHEMBL15302545 | 0.81 | MEN1 (0.32) | MEN1KMT2ATSHR | |
| SCHEMBL3109862 | 0.80 | ACHE (0.33) | ACHEMEN1KMT2ANR1H2NR1H3 | |
| SCHEMBL251739 | 0.80 | ACHE (0.33) | ACHEMEN1KMT2ANR1H2NR1H3 | |
| SCHEMBL6517713 | 0.78 | MEN1 (0.33) | ACHEMEN1KMT2ANR1H2NR1H3 | |
| SCHEMBL15266411 | 0.78 | — | — | |
| SCHEMBL4867088 | 0.78 | — | — | |
| SCHEMBL15302077 | 0.78 | MEN1 (0.33) | MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9745406-B2 | Curable composition | CEMEDINE CO., LTD. (JP) | 2017-08-29 | — | — | US | disclosed |
| EP-2412756-B1 | CURABLE COMPOSITION | CEMEDINE CO LTD (JP) | 2016-12-21 | — | — | EP | disclosed |
| US-8791221-B2 | Addition-curable metallosiloxane compound | DAICEL CORPORATION (JP) | 2014-07-29 | — | — | US | disclosed |
| EP-2650319-A1 | ADDITION-CURABLE METALLOSILOXANE COMPOUND | Daicel Corporation (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-20130267653-A1 | ADDITION-CURABLE METALLOSILOXANE COMPOUND | DAICEL CORPORATION (JP) | 2013-10-10 | — | — | US | disclosed |
| US-8519049-B2 | Curable composition | CEMEDINE CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| CN-103249762-A | Addition-curable metallosiloxane compound | DAICEL CORP | 2013-08-14 | — | — | CN | disclosed |
| US-20120316253-A1 | CURABLE COMPOSITION | SAITO ATSUSHI (JP) | 2012-12-13 | — | — | US | disclosed |
| US-8217130-B2 | Curable composition and method for producing the same | CEMEDINE CO., LTD. (JP) | 2012-07-10 | — | — | US | disclosed |
| EP-2093252-B1 | Curing composition and method for producing curing composition | CEMEDINE CO LTD (JP) | 2012-05-16 | — | — | EP | disclosed |
| EP-2050772-B1 | CURABLE RESIN AND CURABLE COMPOSITION | MITSUI CHEMICALS INC (JP) | 2011-11-30 | — | — | EP | disclosed |
| US-20100267898-A1 | CURABLE COMPOSITION AND METHOD FOR PRODUCING THE SAME | CEMEDINE CO., LTD. | 2010-10-21 | — | — | US | disclosed |
| EP-1650257-B1 | CURING COMPOSITION AND METHOD FOR PRODUCING CURING COMPOSITION | CEMEDINE CO LTD (JP) | 2010-09-08 | — | — | EP | disclosed |
| US-7781559-B2 | Curable composition and method for producing the same | CEMEDINE CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-20100036050-A1 | CURABLE RESIN AND CURABLE COMPOSITION | CEMEDINE CO., LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-2093252-A1 | Curing composition and method for producing curing composition | CEMEDINE CO., LTD. (JP) | 2009-08-26 | — | — | EP | disclosed |
| US-20090118401-A1 | Curable Composition | CEMEDINE CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-2050772-A1 | CURABLE RESIN AND CURABLE COMPOSITION | Mitsui Chemicals Polyurethanes, Inc. (JP) | 2009-04-22 | — | — | EP | disclosed |
| US-20060293456-A1 | Curable composition and method for producing the same | CEMEDINE CO., LTD. (JP) | 2006-12-28 | — | — | US | disclosed |
| EP-1650257-A1 | CURING COMPOSITION AND METHOD FOR PRODUCING CURING COMPOSITION | CEMEDINE CO., LTD. (JP) | 2006-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267653-A1 | ADDITION-CURABLE METALLOSILOXANE COMPOUND | B2M, MSI2, MNS1 | ACHE 3406/4885MEN1 23/4885KMT2A 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.